This development of MET CAR-T represents an innovative approach for treating various solid tumors, exhibiting significant anti-tumor activity in papillary renal cell carcinoma (PRCC), recurrent nasopharyngeal carcinoma (rNPC), Ewing sarcoma (EWS), and gastric cancer (GC) [214,215,216,217]. Here, MET is linked to gastric cancer.